Evidence map›Paper›PMID 33552515›Full record

ReviewSAGE open medicine2021

Reviewing immunopathology characteristics of SARS-CoV-2 for cancer entwisted with SARS-CoV-2.

Hongyan Li, Wanting Lu, Yinyin Li, Yinying Lu, Fei Li

Abstract readReview
In one paragraph

Review in SAGE open medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hongyan LiGeneral Surgery Department, Xuanwu Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-2275-5039
Wanting LuNeurology Department, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yinyin LiComprehensive Liver Cancer Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yinying LuComprehensive Liver Cancer Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Fei LiGeneral Surgery Department, Xuanwu Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In December 2019, the outbreak of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection that started in Wuhan, Hubei Province, China, has spread to all world. Based on the accumulated data and knowledge on the coronavirus infection and immunology characteristics, this review would hope to give some hints on human immune response to SARS-CoV-2 infection in cancer patients. This insight may help in designing the appropriate immune intervention for treatment and the prophylactic/therapeutic methods against cancer under current coronavirus from immunopathology characteristics of SARS-CoV-2 and cancer entwisted with it. We should achieve accurate diagnosis and treatment for cancer patients through advantages of multidisciplinary diagnosis and treatment team. It is believed that we will eventually overcome the epidemic and win in the future.

Indexed as

cancerChinacoronavirusimmunopathologySARS-CoV-2

Identifiers

PMID33552515
PMCPMC7844443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.